Immu Notherapy Drugs Market is expected to grow at a CAGR of 10.1% during the forecast period and the market size is expected to reach nearly US$ 402.52 Bn by 2029. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Immunotherapy Drugs Market is segmented by type of drug, therapy area, end user, and geography. Type of drug segment is sub segmented as monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins and other drugs. Therapy area segment is classified as cancer, autoimmune and inflammatory diseases, infectious diseases and other therapy areas. Cancer sub segment is expected to dominate the market growth during forecast period, owing to increasing preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs. End user segment is divided as Hospitals, Clinics and Other End Users. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa and Latin America.To know about the Research Methodology :- Request Free Sample Report Immunotherapy Drugs are used to improve human immunity system to fight against infectious diseases and cancer as well as to enhance the overall immunity of the body and restricts the growth of the cancer cells. In this treatment, immune cells kill the cancer cells from the body. High prevalence rate of lifestyle diseases and increasing demand for MABS are trending the overall Global Immunotherapy Drugs Market. However, high cost of immunotherapy treatment will restrain the market growth. North America is expected to dominate the Immunotherapy Drugs Market in forecast period followed by Europe and APAC. Technologically advanced research platforms existence and early adoption of highly developed technologies and a supportive economic structure in this region will fuel the Immunotherapy Drugs Market in North America region. key players operated in the market includes DC Therapeutics, Acorda Therapeutics, Ablynx, AB Science, ELI Lilly and Company, Bristol-Myers Squibb, Astrazeneca, Abbvie, Amgen Inc, Glaxosmithkline PLC, Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.), Novartis International AG, Merck & Co., Inc., F. Hoffmann-La Roche AG
Immunotherapy Drugs Market Scope: Inquire before buying
Global Immunotherapy Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 205.25 Bn. Forecast Period 2023 to 2029 CAGR: 10.1% Market Size in 2029: US $ 402.52 Bn. Segments Covered: by Type of Drug Monoclonal Antibodies Adult Vaccines Preventive Vaccines Therapeutic Vaccines Checkpoint Inhibitors Interferons Alpha & Beta Interleukins Other Drugs by Therapy Area Cancer Autoimmune and Inflammatory Diseases Infectious Diseases Other Therapy Areas by End-User Hospitals Clinics Other End Users Immunotherapy Drugs Market, By Region:
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Immunotherapy Drugs Market Key Players:
1. DC Therapeutics 2. Acorda Therapeutics 3. Ablynx 4. AB Science 5. ELI Lilly and Company 6. Bristol-Myers Squibb 7. Astrazeneca 8. Abbvie 9. Amgen Inc 10.Glaxosmithkline PLC 11.Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.) 12.Novartis International AG 13.Merck & Co., Inc. 14.F. Hoffmann-La Roche AG 15.Bayer AG 16.Viatris Inc. 17.Pfizer Inc. 18.Vertex Pharmaceuticals Inc. 19.Boehringer Ingelheim 20.Immatics Biotechnologies 21.BioNTech SE Frequently Asked Questions: 1. Which region has the largest share in Global Immu Notherapy Drugs Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Immu Notherapy Drugs Market? Ans: The Global Immu Notherapy Drugs Market is growing at a CAGR of 10.1% during forecasting period 2023-2029. 3. What is scope of the Global Immu Notherapy Drugs market report? Ans: Global Immu Notherapy Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Immu Notherapy Drugs market? Ans: The important key players in the Global Immu Notherapy Drugs Market are – DC Therapeutics, Acorda Therapeutics, Ablynx, AB Science, ELI Lilly and Company, Bristol-Myers Squibb, Astrazeneca, Abbvie, Amgen Inc, Glaxosmithkline PLC, Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.), Novartis International AG, Merck & Co., Inc., F. Hoffmann-La Roche AG, Bayer AG, Viatris Inc., Pfizer Inc., Vertex Pharmaceuticals Inc., Boehringer Ingelheim, Immatics Biotechnologies, and BioNTech SE 5. What is the study period of this market? Ans: The Global Immu Notherapy Drugs Market is studied from 2022 to 2029.
1. Immu Notherapy Drugs Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Immu Notherapy Drugs Market: Dynamics 2.1. Immu Notherapy Drugs Market Trends by Region 2.1.1. North America Immu Notherapy Drugs Market Trends 2.1.2. Europe Immu Notherapy Drugs Market Trends 2.1.3. Asia Pacific Immu Notherapy Drugs Market Trends 2.1.4. Middle East and Africa Immu Notherapy Drugs Market Trends 2.1.5. South America Immu Notherapy Drugs Market Trends 2.2. Immu Notherapy Drugs Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Immu Notherapy Drugs Market Drivers 2.2.1.2. North America Immu Notherapy Drugs Market Restraints 2.2.1.3. North America Immu Notherapy Drugs Market Opportunities 2.2.1.4. North America Immu Notherapy Drugs Market Challenges 2.2.2. Europe 2.2.2.1. Europe Immu Notherapy Drugs Market Drivers 2.2.2.2. Europe Immu Notherapy Drugs Market Restraints 2.2.2.3. Europe Immu Notherapy Drugs Market Opportunities 2.2.2.4. Europe Immu Notherapy Drugs Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Immu Notherapy Drugs Market Drivers 2.2.3.2. Asia Pacific Immu Notherapy Drugs Market Restraints 2.2.3.3. Asia Pacific Immu Notherapy Drugs Market Opportunities 2.2.3.4. Asia Pacific Immu Notherapy Drugs Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Immu Notherapy Drugs Market Drivers 2.2.4.2. Middle East and Africa Immu Notherapy Drugs Market Restraints 2.2.4.3. Middle East and Africa Immu Notherapy Drugs Market Opportunities 2.2.4.4. Middle East and Africa Immu Notherapy Drugs Market Challenges 2.2.5. South America 2.2.5.1. South America Immu Notherapy Drugs Market Drivers 2.2.5.2. South America Immu Notherapy Drugs Market Restraints 2.2.5.3. South America Immu Notherapy Drugs Market Opportunities 2.2.5.4. South America Immu Notherapy Drugs Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Immu Notherapy Drugs Industry 2.8. Analysis of Government Schemes and Initiatives For Immu Notherapy Drugs Industry 2.9. Immu Notherapy Drugs Market Trade Analysis 2.10. The Global Pandemic Impact on Immu Notherapy Drugs Market 3. Immu Notherapy Drugs Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 3.1.1. Monoclonal Antibodies 3.1.2. Adult Vaccines 3.1.3. Preventive Vaccines 3.1.4. Therapeutic Vaccines 3.1.5. Checkpoint Inhibitors 3.1.6. Interferons Alpha & Beta 3.1.7. Interleukins 3.1.8. Other Drugs 3.2. Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 3.2.1. Cancer 3.2.2. Autoimmune and Inflammatory Diseases 3.2.3. Infectious Diseases 3.2.4. Other Therapy Areas 3.3. Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 3.3.1. Hospitals 3.3.2. Clinics 3.3.3. Other End Users 3.4. Immu Notherapy Drugs Market Size and Forecast, by Region (2022-2029) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Immu Notherapy Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 4.1.1. Monoclonal Antibodies 4.1.2. Adult Vaccines 4.1.3. Preventive Vaccines 4.1.4. Therapeutic Vaccines 4.1.5. Checkpoint Inhibitors 4.1.6. Interferons Alpha & Beta 4.1.7. Interleukins 4.1.8. Other Drugs 4.2. North America Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 4.2.1. Cancer 4.2.2. Autoimmune and Inflammatory Diseases 4.2.3. Infectious Diseases 4.2.4. Other Therapy Areas 4.3. North America Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 4.3.1. Hospitals 4.3.2. Clinics 4.3.3. Other End Users 4.4. North America Immu Notherapy Drugs Market Size and Forecast, by Country (2022-2029) 4.4.1. United States 4.4.1.1. United States Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 4.4.1.1.1. Monoclonal Antibodies 4.4.1.1.2. Adult Vaccines 4.4.1.1.3. Preventive Vaccines 4.4.1.1.4. Therapeutic Vaccines 4.4.1.1.5. Checkpoint Inhibitors 4.4.1.1.6. Interferons Alpha & Beta 4.4.1.1.7. Interleukins 4.4.1.1.8. Other Drugs 4.4.1.2. United States Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 4.4.1.2.1. Cancer 4.4.1.2.2. Autoimmune and Inflammatory Diseases 4.4.1.2.3. Infectious Diseases 4.4.1.2.4. Other Therapy Areas 4.4.1.3. United States Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 4.4.1.3.1. Hospitals 4.4.1.3.2. Clinics 4.4.1.3.3. Other End Users 4.4.2. Canada 4.4.2.1. Canada Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 4.4.2.1.1. Monoclonal Antibodies 4.4.2.1.2. Adult Vaccines 4.4.2.1.3. Preventive Vaccines 4.4.2.1.4. Therapeutic Vaccines 4.4.2.1.5. Checkpoint Inhibitors 4.4.2.1.6. Interferons Alpha & Beta 4.4.2.1.7. Interleukins 4.4.2.1.8. Other Drugs 4.4.2.2. Canada Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 4.4.2.2.1. Cancer 4.4.2.2.2. Autoimmune and Inflammatory Diseases 4.4.2.2.3. Infectious Diseases 4.4.2.2.4. Other Therapy Areas 4.4.2.3. Canada Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 4.4.2.3.1. Hospitals 4.4.2.3.2. Clinics 4.4.2.3.3. Other End Users 4.4.3. Mexico 4.4.3.1. Mexico Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 4.4.3.1.1. Monoclonal Antibodies 4.4.3.1.2. Adult Vaccines 4.4.3.1.3. Preventive Vaccines 4.4.3.1.4. Therapeutic Vaccines 4.4.3.1.5. Checkpoint Inhibitors 4.4.3.1.6. Interferons Alpha & Beta 4.4.3.1.7. Interleukins 4.4.3.1.8. Other Drugs 4.4.3.2. Mexico Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 4.4.3.2.1. Cancer 4.4.3.2.2. Autoimmune and Inflammatory Diseases 4.4.3.2.3. Infectious Diseases 4.4.3.2.4. Other Therapy Areas 4.4.3.3. Mexico Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 4.4.3.3.1. Hospitals 4.4.3.3.2. Clinics 4.4.3.3.3. Other End Users 5. Europe Immu Notherapy Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.2. Europe Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.3. Europe Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4. Europe Immu Notherapy Drugs Market Size and Forecast, by Country (2022-2029) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.1.2. United Kingdom Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.1.3. United Kingdom Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.2. France 5.4.2.1. France Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.2.2. France Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.2.3. France Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.3. Germany 5.4.3.1. Germany Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.3.2. Germany Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.3.3. Germany Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.4. Italy 5.4.4.1. Italy Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.4.2. Italy Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.4.3. Italy Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.5. Spain 5.4.5.1. Spain Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.5.2. Spain Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.5.3. Spain Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.6. Sweden 5.4.6.1. Sweden Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.6.2. Sweden Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.6.3. Sweden Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.7. Austria 5.4.7.1. Austria Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.7.2. Austria Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.7.3. Austria Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 5.4.8.2. Rest of Europe Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 5.4.8.3. Rest of Europe Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6. Asia Pacific Immu Notherapy Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.2. Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.3. Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4. Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by Country (2022-2029) 6.4.1. China 6.4.1.1. China Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.1.2. China Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.1.3. China Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.2. S Korea 6.4.2.1. S Korea Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.2.2. S Korea Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.2.3. S Korea Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.3. Japan 6.4.3.1. Japan Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.3.2. Japan Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.3.3. Japan Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.4. India 6.4.4.1. India Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.4.2. India Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.4.3. India Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.5. Australia 6.4.5.1. Australia Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.5.2. Australia Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.5.3. Australia Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.6. Indonesia 6.4.6.1. Indonesia Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.6.2. Indonesia Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.6.3. Indonesia Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.7. Malaysia 6.4.7.1. Malaysia Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.7.2. Malaysia Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.7.3. Malaysia Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.8. Vietnam 6.4.8.1. Vietnam Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.8.2. Vietnam Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.8.3. Vietnam Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.9. Taiwan 6.4.9.1. Taiwan Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.9.2. Taiwan Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.9.3. Taiwan Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 6.4.10.2. Rest of Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 6.4.10.3. Rest of Asia Pacific Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 7. Middle East and Africa Immu Notherapy Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 7.2. Middle East and Africa Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 7.3. Middle East and Africa Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 7.4. Middle East and Africa Immu Notherapy Drugs Market Size and Forecast, by Country (2022-2029) 7.4.1. South Africa 7.4.1.1. South Africa Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 7.4.1.2. South Africa Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 7.4.1.3. South Africa Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 7.4.2. GCC 7.4.2.1. GCC Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 7.4.2.2. GCC Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 7.4.2.3. GCC Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 7.4.3. Nigeria 7.4.3.1. Nigeria Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 7.4.3.2. Nigeria Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 7.4.3.3. Nigeria Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 7.4.4.2. Rest of ME&A Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 7.4.4.3. Rest of ME&A Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 8. South America Immu Notherapy Drugs Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 8.2. South America Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 8.3. South America Immu Notherapy Drugs Market Size and Forecast, by End-User(2022-2029) 8.4. South America Immu Notherapy Drugs Market Size and Forecast, by Country (2022-2029) 8.4.1. Brazil 8.4.1.1. Brazil Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 8.4.1.2. Brazil Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 8.4.1.3. Brazil Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 8.4.2. Argentina 8.4.2.1. Argentina Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 8.4.2.2. Argentina Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 8.4.2.3. Argentina Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Immu Notherapy Drugs Market Size and Forecast, by Type of Drug (2022-2029) 8.4.3.2. Rest Of South America Immu Notherapy Drugs Market Size and Forecast, by Therapy Area (2022-2029) 8.4.3.3. Rest Of South America Immu Notherapy Drugs Market Size and Forecast, by End-User (2022-2029) 9. Global Immu Notherapy Drugs Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Immu Notherapy Drugs Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. DC Therapeutics 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Acorda Therapeutics 10.3. Ablynx 10.4. AB Science 10.5. ELI Lilly and Company 10.6. Bristol-Myers Squibb 10.7. Astrazeneca 10.8. Abbvie 10.9. Amgen Inc 10.10. Glaxosmithkline PLC 10.11. Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.) 10.12. Novartis International AG 10.13. Merck & Co., Inc. 10.14. F. Hoffmann-La Roche AG 10.15. Bayer AG 10.16. Viatris Inc. 10.17. Pfizer Inc. 10.18. Vertex Pharmaceuticals Inc. 10.19. Boehringer Ingelheim 10.20. Immatics Biotechnologies 10.21. BioNTech SE 11. Key Findings 12. Industry Recommendations 13. Immu Notherapy Drugs Market: Research Methodology 14. Terms and Glossary